Drug Discovery & DDS– category –
-
Modular In Vivo Antibody-ADC Click Strategy Reverses Drug Resistance in Tumors
PubMed (Nature Chemical Biology) USA Overview Researchers have introduced an in vivo bioorthogonal ligation strategy to generate functional antibody-drug conjugate (ADC) click constructs following systemic administration. This modular pl... -
AI Drug Discovery Enters “Clinical Proof Era” in 2026 with Insilico’s Rentosertib in Phase 3 and Isomorphic Labs’ IsoDDE Nearing Clinical Entry
PharmaADC Unknown Overview The article highlights 2026 as the "era of clinical proof" for AI drug discovery, exemplified by Insilico Medicine's AI-developed rentosertib entering Phase 3 trials for idiopathic pulmonary fibrosis (IPF) in J... -
Chai Discovery Raises $400M in Series C, Valuation Reaches $3.8B, Announces Novartis Collaboration
AIPressRoom USA Overview Chai Discovery has raised $400 million in a Series C round, bringing the AI drug discovery company's valuation to $3.8 billion. The company, which uses generative AI to design new antibodies and proteins, announc... -
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) in Pediatric Patients with Serious Gram-Negative Infections
Shionogi Japan Overview The FDA has accepted Shionogi's supplemental New Drug Application (sNDA) for Fetroja® (cefiderocol) to treat serious infections caused by susceptible Gram-negative bacteria in pediatric patients. This submission a... -
Xaira Emerges with $1.3 Billion Funding, Seeks Preclinical Data Partners to Fortify AI Drug Discovery Platform
BioNucleus Briefing USA Overview Xaira, an AI drug discovery company, has emerged from stealth after raising $1.3 billion and is actively seeking partners to contribute preclinical datasets to strengthen its AI platform. Emphasizing data... -
Optimal Payload Linker Selection is Critical for ADC Development, Balancing Efficacy, Safety, and Stability
Chemexpress China Overview This guide highlights the critical role of selecting the right payload linker for successful antibody-drug conjugate (ADC) programs. Linker design dictates the balance between efficacy, safety, stability, and m... -
Alloy Therapeutics Unveils AntiClastic™ Cyclic RNA Platform for Enhanced Potency and Reduced Off-Target Effects in Next-Gen RNA Medicines
Alloy Therapeutics USA Overview Alloy Therapeutics introduced its AntiClastic™ Cyclic Oligonucleotide platform, which reconfigures ASOs, siRNAs, and sgRNAs into proprietary cyclic architectures. This technology aims to enhance potency an... -
Nurix Therapeutics’ Bexobrutideg Shows 83% ORR and 22.1 Months PFS in Relapsed/Refractory CLL/SLL Phase 1 Study
Nurix Therapeutics USA Overview Nurix Therapeutics reported updated clinical data from its NX-5948-301 Phase 1a/1b study, showing durable responses and a favorable tolerability profile for bexobrutideg in relapsed/refractory CLL/SLL pati... -
Merck/Kelun-Biotech ADC Candidate Sac-TMT Demonstrates Superior Progression-Free Survival Over Chemotherapy in China Phase 3 Lung Cancer Study
Endpoints News USA Overview Merck's partner Kelun-Biotech announced positive Phase 3 study results in China for sac-TMT, an experimental antibody-drug conjugate (ADC). In non-squamous non-small cell lung cancer, sac-TMT combined with imm... -
Ractigen’s SOD1-ALS siRNA Therapy RAG-17 Shows Significant SOD1 Reduction and Favorable Safety in Phase 1, Published in Nature Medicine
BioSpace USA Overview Ractigen Therapeutics published preclinical and positive First-in-Human Phase 1 clinical data for RAG-17, an siRNA therapy for SOD1-ALS, in Nature Medicine. The trial met primary safety endpoints with no serious adv...
